15 Reasons we need new antimalarials
As we count down to our 15th anniversary, each month we reflect on some of our favourite 15 things.
MMV’s R&D portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Here are 15 reasons we need new antimalarials.
Slideshow created January 2015
Photo credits: Slide 1 - Lemu Golassa; Slide 2 - Feliciano Monti; Slide 3 - MMV; Slide 4 - MMV; Slide 5 - MMV; Slide 6 - MMV; Slide 7 - BMC St Jude; Slide 8 - Jennifer Jackson; Slide 9 - Merck Serono; Slide 10 - Anna Wang; Slide 11 - Ben Moldenhauer; Slide 12 - Anna Wang; Slide 13 - Anna Wang; Slide 14 - MMV; Slide 15 - MMV
More information is available on the Paul-Ehrlich-Gesellschaft (P-E-G) website.
More information about this event is available on the ASTMH website.